Atherosclerotic Cardiovascular Disease

The pooled analysis of BROOKLYN and BROADWAY data outline obicetrapib’s impact on HbA1c reduction and a trend toward lower new-onset diabetes risk.

A recent study reveals a significant rise in cardiac deaths at home since the COVID-19 pandemic, highlighting urgent healthcare gaps.

Yale researchers unveil a groundbreaking 3D-bioprinted synthetic aorta, promising revolutionary advancements in cardiovascular disease treatment and patient care.

Discover the critical role of Lp(a) measurement in assessing cardiovascular risk and its potential impact on CVD prevention strategies.

Calprotectin emerges as a promising biomarker for predicting atherosclerotic cardiovascular disease risk, independent of traditional risk factors.

Latest analysis of the HELIOS-B trial finds vutrisiran significantly lowers mortality and cardiovascular events in patients with ATTR-CM.

Olezarsen shows promising results in reducing triglyceride levels for patients with moderate hypertriglyceridemia, offering hope for better cardiovascular health.

Adult-onset T1D significantly raises cardiovascular disease and mortality risks, highlighting the need for improved management and prevention strategies.

New findings reveal that timing of antihypertensive medication—bedtime vs. morning—shows no significant impact on health outcomes for frail older adults.

Crinecerfont significantly reduces glucocorticoid use in pediatric CAH while improving hormone levels, enhancing long-term patient outcomes.

Stay updated with the latest healthcare breakthroughs, including cholesterol treatments and innovative therapies for AMD and psoriasis, in this week's roundup.

FDA approves 12.5 mg chlorthalidone tablets, enhancing hypertension treatment options and aligning with clinical guidelines for better patient outcomes.

Our April 2025 month in review highlights breakthroughs in gene therapy, device innovations, and evolving treatment strategies for cardiology.

New research links increased dietary selenium intake to reduced cardiovascular disease risk, highlighting its potential benefits for heart health.

Using the American Heart Association’s Life’s Essential 8 model, researchers indicated that preventative action early in life can reduce chances of developing cardiovascular disease later.

Simple choices like improving diet and increasing exercise can influence a healthy individual’s risk of developing cardiovascular disease.

A secondary analysis of the data collected by the DASH-Sodium trial indicates that dieting and sodium intake limits are additive in their effects on ASCVD risk.

Orchestra BioMed’s Breakthrough Device designation could apply to nearly 8 million patients with uncontrolled hypertension and increased cardiovascular risk

Anita Radhakrishnan, MD, leads a community screening effort to detect early heart disease in underserved populations in Pittsburgh.

Anemia can moderate the association between both conditions, increasing the risk of atherosclerotic cardiovascular disease.

Label updates simplify twice-yearly echo monitoring for eligible patients in the maintenance phase and expand eligibility with reduced contraindications.

Radhakrishnan describes a unique initiative in Pittsburgh promoting health equity and closing the gap in cardiovascular health disparities.

This episode spotlights a pair of studies examining use of semaglutide from the American College of Cardiology's 2025 Scientific Sessions.

Individuals treated with ezetimibe shortly after myocardial infarction experience an improved prognosis versus those who receive delayed treatment or none at all.

Bristol Myers Squibb says mavacamten missed dual primary endpoints in Phase 3 ODYSSEY-HCM trial for symptomatic non-obstructive HCM.